Evidence map›Paper›PMID 41428981›Full record

ArticleNeurology2026

Utility of the Amygdalar Atrophy Scale to Identify Patients With Limbic-Predominant Age-Related TDP-43 Encephalopathy in a Memory Clinic.

Fausto Roveta, Francesca B Pizzini, Valerio Natale, Max Scheffler, Valentina Garibotto, Augusto J Mendes, Chen Wang, Aurelien Lathuiliere, Christian Chicherio, Innocenzo Rainero and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Fausto RovetaAging Brain and Memory Clinic, Department of Neuroscience "Rita Levi-Montalcini", University of Turin, Italy.ORCID 0000-0001-7230-7819
Francesca B PizziniDepartment of Engineering for Innovation Medicine, University of Verona, Italy.ORCID 0000-0002-6285-0989
Valerio NataleRadiology, Department of Diagnostic and Public Health, University of Verona, Italy.
Max SchefflerDivision of Radiology, Geneva University Hospitals, Switzerland.ORCID 0000-0003-2274-5129
Valentina GaribottoDivision of Nuclear Medicine and Molecular Imaging, Geneva University Hospitals, Switzerland.ORCID 0000-0003-2422-698X
Augusto J MendesGeneva Memory Center, Department of Rehabilitation and Geriatrics, Geneva University Hospitals, Switzerland.ORCID 0000-0002-9497-0707
Chen WangGeneva Memory Center, Department of Rehabilitation and Geriatrics, Geneva University Hospitals, Switzerland.
Aurelien LathuiliereGeneva Memory Center, Department of Rehabilitation and Geriatrics, Geneva University Hospitals, Switzerland.
Christian ChicherioGeneva Memory Center, Department of Rehabilitation and Geriatrics, Geneva University Hospitals, Switzerland.
Innocenzo RaineroAging Brain and Memory Clinic, Department of Neuroscience "Rita Levi-Montalcini", University of Turin, Italy.
Giovanni B FrisoniGeneva Memory Center, Department of Rehabilitation and Geriatrics, Geneva University Hospitals, Switzerland.ORCID 0000-0001-7075-7082
Federica RibaldiGeneva Memory Center, Department of Rehabilitation and Geriatrics, Geneva University Hospitals, Switzerland.ORCID 0000-0001-9208-4472

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesLimbic-predominant age-related TDP-43 encephalopathy (LATE) is a neurodegenerative condition often overlapping clinically with Alzheimer disease (AD). No established in vivo biomarkers exist for LATE. The amygdalar atrophy scale (AAS) is a visual MRI rating tool scoring the amygdala as AAS

methodsThis retrospective study included individuals attending the Geneva Memory Center (2014-2022) who underwent T1-weighted MRI, as well as clinical and neuropsychological assessments. Participants were categorized with an etiologic grouping defined as No-AD/No-LATE (AAS

resultsThe analytic sample included 469 participants (mean age 71.2 ± 8.5 years, 53% female). The No-AD/No-LATE group exhibited the highest MMSE scores (N = 181, 27.9 ± 2.2), outperforming AD (N = 146, 24.2 ± 4.9), LATE (N = 36, 26.2 ± 3.2), and AD/LATE (N = 106, 22.5 ± 5.3) groups ( DISCUSSION: Patients identified as LATE by the integration of AAS with AD biomarkers had generally mild amnestic cognitive impairment, significant limbic atrophy, and slow decline over time, all features consistent with previous autopsy series. Moreover, AD/LATE cases were more impaired than those with LATE or AD alone. Prospective and neuropathologic validation is warranted.

Indexed as

AmygdalaTDP-43 ProteinopathiesAgedAged, 80 and overAlzheimer DiseaseAtrophyDementiaFemaleHumansMagnetic Resonance ImagingMaleMiddle AgedNeuropsychological TestsRetrospective Studies

Identifiers

PMID41428981
PMCPMC12746730

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.